Serum Gal-9 levels could predict the development and severity of NAFLD in RA patients, although the causative role of Gal-9 and FABP1 in RA-related NAFLD still needs further investigation. Here, LGALS9 is linked to metabolic dysfunction-associated steatotic liver disease.